Evaluation of MR-safe bioptomes for MR-guided endomyocardial biopsy in minipigs: a potential radiation-free clinical approach

Angelika Svetlove, Christian Ritter, Christian Dullin, Michael Schmid, Senta Schauer, Johannes Uihlein, Martin Uecker, Matthias Mietsch, Christine Stadelmann, Joachim Lotz, Christina Unterberg‐BuchwaldEuropean 2023 · DOI

Abstract

Novel MR-compatible bioptomes show promise for a clinical application. Synchrotron radiation computed microtomography (SRµCT) enabled detailed analysis of endomyocardial biopsies. The bioptomes showed adequate in vivo performance without major complications in a minipig model.

Introduction

Endomyocardial biopsy (EMB) remains the gold standard for diagnosing myocarditis, heart transplant rejection, and various cardiomyopathies. Currently, these procedures are performed under fluoroscopic (X-ray) guidance. However, this approach entails significant ionizing radiation exposure for both patients and physicians. Furthermore, X-ray imaging provides poor soft-tissue contrast, often resulting in "blind" sampling and low diagnostic yields, particularly for focal diseases.

Magnetic Resonance Imaging (MRI) offers a compelling alternative due to its superior soft-tissue contrast and lack of ionizing radiation. Transitioning to MR-guided EMB requires the development of MR-safe biopsy tools, as standard stainless steel bioptomes are paramagnetic and pose safety risks in the MRI environment. This study evaluates two novel titanium-based bioptome prototypes designed for real-time MR-guided procedures.

Materials and Methods

Two MR-safe bioptome prototypes were developed:

  • B1 ("Grind-Grind"): Featuring two sharpened jaws.
  • B2 ("Grind-Anvil"): Featuring one sharpened jaw and one flat anvil surface.

The evaluation followed a multi-stage protocol. Initially, ex vivo biopsies were performed on explanted pig hearts using a mechanical jig. To assess tissue quality beyond traditional 2D histology, the researchers utilized Phase-contrast Synchrotron Radiation Computed Microtomography (SRµCT) at the ELETTRA synchrotron. This allowed for high-resolution (2 µm voxel size) 3D analysis of specimen volume and structural integrity, specifically looking for "crush artifacts."

Subsequently, in vivo testing was conducted in six healthy Göttingen minipigs using a 3T clinical MRI scanner. Bioptomes were tracked using passive MR-visible markers. Finally, standard H&E staining was performed to confirm diagnostic utility.

Results

The "grind-grind" (B1) design demonstrated clear superiority over the "grind-anvil" (B2) design. In vivo, the B1 prototype achieved a cutting success rate of 91.7%, compared to 86.2% for B2. More importantly, B1 samples were rated with a 95.3% diagnostic value, significantly higher than the 87.5% observed for B2.

SRµCT analysis of biopsy samples. (e, f) 3D volume renderings of biopsies. (g, h) Cross-sectional slices highlighting internal tissue structure and integrity.

The SRµCT analysis was pivotal in identifying subtle differences in tissue quality. While 2D histology might overlook compression damage, 3D imaging revealed that the B2 design caused significantly higher tissue compression (p=0.0011). In contrast, the B1 design produced larger specimens with structural integrity comparable to standard clinical steel bioptomes (p=0.822).

Real-time MR guidance allowed interventionalists to visualize the bioptome's position and state (open/closed) relative to cardiac landmarks, such as the papillary muscles, enhancing procedural precision. The in vivo procedures were 100% successful with no major complications.

Discussion

This study validates the feasibility of radiation-free, MR-guided EMB using novel MR-safe bioptomes. The B1 "grind-grind" design is particularly promising, offering high-quality tissue samples and reliable performance. The use of SRµCT provided a more rigorous assessment of biopsy quality than traditional methods, highlighting the importance of tool design in preserving tissue architecture.

Despite these successes, challenges remain for clinical translation. MR-guided EMB is currently slower and more costly than fluoroscopic methods. Additionally, the lack of commercially available, MR-safe deflectable guiding catheters limits precise steering. Future studies should focus on workflow optimization, catheter development, and validation in diseased animal models to demonstrate the ability to target specific lesions under MR guidance.

Summary updated

Abstract

• Novel MR-compatible bioptomes show promise for a clinical application. • SRµCT enabled detailed analysis of endomyocardial biopsies. • The bioptomes showed adequate in vivo performance without major complications.
BibTeX
@inproceedings{svetlove2023evaluation,
  author = {Angelika Svetlove and Christian Ritter and Christian Dullin and Michael Schmid and Senta Schauer and Johannes Uihlein and Martin Uecker and Matthias Mietsch and Christine Stadelmann and Joachim Lotz and Christina Unterberg‐Buchwald},
  title = {{Evaluation of MR-safe bioptomes for MR-guided endomyocardial biopsy in minipigs: a potential radiation-free clinical approach}},
  booktitle = {European},
  year = {2023},
  doi = {10.1186/s41747-023-00391-4},
}
Figure